:

AI WILL FIND CANCER CURE IN OUR LIFETIME, ARM CEO SAYS

AI DESK1 MIN READ
TUE, SEP 8, 2026

■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE

Rene Haas, chief executive of chip designer Arm Holdings, claims artificial intelligence will discover a cancer cure within our lifetimes. He also predicts humanoid robots could become widespread within five years.

Haas said that modelling how DNA markers are affected by cancer is currently too complex for humans or existing technology to solve. However, he believes advancing AI systems will overcome this barrier. The Arm Holdings boss made the comments as part of broader remarks on AI's potential across industries. Beyond medical breakthroughs, Haas suggested the technology will enable rapid commercialization of humanoid robots—a shift he pegged at a five-year timeframe. Arm designs chips powering everything from smartphones to data centers. The company's positioning in the semiconductor industry gives Haas insight into computational trends, though his timeline predictions remain speculative. The comments reflect growing confidence among tech leaders in AI's capability to accelerate scientific discovery, particularly in fields requiring analysis of vast datasets and complex biological systems.

■ SOURCES

The Guardian — Technology

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE AI DESK

Students using AI chatbots for schoolwork score lower than peers who don't, according to the OECD's latest educational report. The findings represent some of the strongest evidence yet that AI tools may harm academic performance.

JUST NOWAI Desk

French AI startup Mistral secured €3 billion in Series D funding at a €21 billion valuation, nearly doubling its value in a year. The round, led by Samsung, marks a shift toward data center infrastructure as the company expands beyond model development.

6H AGOAI Desk

Anthropic has decided against acquiring AI startup Decart AI, according to sources familiar with the matter. The deal would have valued the company at $6 billion.

10H AGOAI Desk

An experimental drug designed by AI appears to reverse biological aging markers in early trials, with independent aging clocks suggesting treated patients were up to six years biologically younger than those on placebo.

15H AGOAI Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.